Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

详细信息    查看全文

• 作者：Toshiaki Watanabe (1)
  Michio Itabashi (2)
  Yasuhiro Shimada (3)
  Shinji Tanaka (4)
  Yoshinori Ito (5)
  Yoichi Ajioka (6)
  Tetsuya Hamaguchi (3)
  Ichinosuke Hyodo (7)
  Masahiro Igarashi (8)
  Hideyuki Ishida (9)
  Soichiro Ishihara (1)
  Megumi Ishiguro (10)
  Yukihide Kanemitsu (11)
  Norihiro Kokudo (12)
  Kei Muro (13)
  Atsushi Ochiai (14)
  Masahiko Oguchi (15)
  Yasuo Ohkura (16)
  Yutaka Saito (17)
  Yoshiharu Sakai (18)
  Hideki Ueno (19)
  Takayuki Yoshino (20)
  Narikazu Boku (21)
  Takahiro Fujimori (22)
  Nobuo Koinuma (23)
  Takayuki Morita (24)
  Genichi Nishimura (25)
  Yuh Sakata (26)
  Keiichi Takahashi (27)
  Osamu Tsuruta (28)
  Toshiharu Yamaguchi (29)
  Masahiro Yoshida (30)
  Naohiko Yamaguchi (31)
  Kenjiro Kotake (32)
  Kenichi Sugihara (10)
  Japanese Society for Cancer of the Colon and Rectum
  
  1. Department of Surgical Oncology ; Graduate School of Medicine ; The University of Tokyo ; 7-3-1 Hongo ; Bunkyo-ku ; Tokyo ; 113-8655 ; Japan
  2. Department of Surgery 2 ; Tokyo Women鈥檚 Medical University ; Tokyo ; Japan
  3. Division of Gastrointestinal Medical Oncology ; National Cancer Center Hospital ; Tokyo ; Japan
  4. Department of Endoscopy ; Hiroshima University Hospital ; Hiroshima ; Japan
  5. Department of Radiation Oncology ; National Cancer Center Hospital ; Tokyo ; Japan
  6. Division of Molecular and Diagnostic Pathology ; Graduate School of Medical and Dental Sciences ; Niigata University ; Niigata ; Japan
  7. Division of Gastroenterology ; Graduate School of Comprehensive Human Sciences ; University of Tsukuba ; Ibaraki ; Japan
  8. Department of Endoscopy ; The Cancer Institute Hospital ; Japanese Foundation for Cancer Research ; Tokyo ; Japan
  9. Department of Digestive Tract and General Surgery ; Saitama Medical Center ; Saitama Medical University ; Saitama ; Japan
  10. Department of Surgical Oncology ; Graduate School ; Tokyo Medical and Dental University ; Tokyo ; Japan
  11. Colorectal Surgery Division ; National Cancer Center Hospital ; Tokyo ; Japan
  12. Hepato-Biliary-Pancreatic Surgery Division ; Artificial Organ and Transplantation Division ; Department of Surgery ; Graduate School of Medicine ; The University of Tokyo ; Tokyo ; Japan
  13. Department of Clinical Oncology ; Aichi Cancer Center Hospital ; Nagoya ; Japan
  14. Pathology Division ; Research Center for Innovative Oncology ; National Cancer Centre Hospital East ; Chiba ; Japan
  15. Radiation Oncology Department ; The Cancer Institute Hospital ; Japanese Foundation for Cancer Research ; Tokyo ; Japan
  16. Department of Pathology ; Kyorin University School of Medicine ; Tokyo ; Japan
  17. Endoscopy Division ; National Cancer Center Hospital ; Tokyo ; Japan
  18. Department of Surgery ; Kyoto University ; Kyoto ; Japan
  19. Department of Surgery ; National Defense Medical College ; Saitama ; Japan
  20. Department of Gastroenterology and Gastrointestinal Oncology ; National Cancer Center Hospital East ; Chiba ; Japan
  21. Department of Clinical Oncology ; St. Marianna University ; Kawasaki ; Japan
  22. Department of Surgical and Molecular Pathology ; Dokkyo Medical University School of Medicine ; Tochigi ; Japan
  23. Department of Health Administration and Policy ; Tohoku Pharmaceutical University ; Miyagi ; Japan
  24. Department of Surgery ; Cancer Center ; Aomori Prefectural Central Hospital ; Aomori ; Japan
  25. Department of Surgery ; Japanese Red Cross Kanazawa Hospital ; Ishikawa ; Japan
  26. CEO ; Misawa City Hospital ; Aomori ; Japan
  27. Department of Surgery ; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital ; Tokyo ; Japan
  28. Division of GI Endoscopy ; Kurume University School of Medicine ; Fukuoka ; Japan
  29. Department of Gastroenterological Surgery ; The Cancer Institute Hospital ; Japanese Foundation for Cancer Research ; Tokyo ; Japan
  30. Department of Hemodialysis and Surgery ; Chemotherapy Research Institute ; International University of Health and Welfare ; Chiba ; Japan
  31. Library ; Toho University Medical Center Sakura Hospital ; Chiba ; Japan
  32. Department of Surgery ; Tochigi Cancer Center ; Tochigi ; Japan
  
• 关键词：Colorectal cancer ; Guideline ; Surgery ; Chemotherapy ; Endoscopy ; Radiotherapy
• 刊名：International Journal of Clinical Oncology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：20
• 期：2
• 页码：207-239
• 全文大小：1,540 KB
• 参考文献：1. Japanese Society for Cancer of the Colon and Rectum (2014) JSCCR Guidelines 2014 for the Treatment of Colorectal Cancer. Kanehara and Co. Ltd, Tokyo
  2. Fukui, T, Yamaguchi, N, Morizane, T (2014) Minds handbook for clinical practice guideline development 2014. Igaku Shoin, Tokyo
  3. Aihara, M, Mihara, H, Murayama, T (2010) GRADE System for clinical practice guideline鈥攖herapeutic intervention. Toppan Media, Hirosaki
  4. Atkins, D, Best, D, Briss, PA (2004) The GRADE* Working Group: Grading quality of evidence and strength of recommendations. BMJ 328: pp. 1490-1494
  5. Guyatt, GH, Oxman, AD, Vist, G (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: pp. 924-926
  6. Guyatt, GH, Oxman, AD, Kunz, R (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations: what is 鈥渜uality of evidence鈥?and why is it important to clinicians?. BMJ 336: pp. 995-998
  7. Schunemann, HJ, Oxman, AD, Brozek, J (2008) GRADE Working Group: Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336: pp. 1106-1110
  8. Guyatt, GH, Oxman, AD, Kunz, R (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations: Incorporating considerations of resources use into grading recommendations. BMJ 336: pp. 1170-1173
  9. Guyatt, GH, Oxman, AD, Kunz, R (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations: going from evidence to recommendations. BMJ 336: pp. 1049-1051
  10. Jaeschke, R, Guyatt, GH, Dellinger, P (2008) GRADE Working Group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337: pp. a744
  11. Guyatt, G, Oxman, AD, Akl, EA (2011) GRADE guidelines: 1. Introduction鈥揋RADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: pp. 383-394
  12. Guyatt, GH, Oxman, AD, Kunz, R (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64: pp. 395-400
  13. Balshem, H, Helfand, M, Schunemann, HJ (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64: pp. 401-406
  14. Guyatt, GH, Oxman, AD, Vist, G (2011) GRADE guidelines: 4. Rating the quality of evidence鈥撯€搒tudy limitations (risk of bias). J Clin Epidemiol 64: pp. 407-415
  15. Guyatt, GH, Oxman, AD, Montori, V (2011) GRADE guidelines: 5. Rating the quality of evidence鈥撯€損ublication bias. J Clin Epidemiol 64: pp. 1277-1282
  16. Guyatt, GH, Oxman, AD, Kunz, R (2011) GRADE guidelines: 6. Rating the quality of evidence imprecision. J Clin Epidemiol 64: pp. 1283-1293
  17. Guyatt, GH, Oxman, AD, Kunz, R (2011) GRADE Working Group: GRADE guidelines: 7. Rating the quality of evidence鈥撯€搃nconsistency. J Clin Epidemiol 64: pp. 1294-1302
  18. Guyatt, GH, Oxman, AD, Kunz, R (2011) GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence鈥撯€搃ndirectness. J Clin Epidemiol 64: pp. 1303-1310
  19. Guyatt, GH, Oxman, AD, Sultan, S (2011) GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64: pp. 1311-1316
  20. Brunetti, M, Shemilt, I, Pregno, S (2013) GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 66: pp. 140-150
  21. Guyatt, G, Oxman, AD, Sultan, S (2013) GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66: pp. 151-157
  22. Guyatt, G, Oxman, AD, Santesso, N (2013) GRADE guidelines: 12. Preparing summary of findings tables鈥揵inary outcomes. J Clin Epidemiol 66: pp. 158-172
  23. Thorlund, K, Oxman, AD, Walter, SD (2013) GRADE guidelines: 13. Preparing summary of findings tables-continuous outcomes. J Clin Epidemiol 66: pp. 173-183
  24. Andrews, J, Guyatt, G, Oxman, AD (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations J. Clin Epidemiol 66: pp. 719-725
  25. Andrews, JC, Schunemann, HJ, Oxman, AD (2013) GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation鈥檚 direction and strength. J Clin Epidemiol 66: pp. 726-735
  26. Japanese Society for Cancer of the Colon and Rectum (2013) Japanese classification of colorectal carcinoma. The 8th Edition. Kanehara & CO., LTD. Tokyo
  27. Tanaka, S, Oka, S, Chayama, K (2008) Colorectal endoscopic submucosal dissection (ESD): the present status and future perspective including its differentiation from endoscopic mucosal resection (EMR). J Gastroenterol 43: pp. 641-651
  28. Kudo, S (1993) Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 25: pp. 455-461
  29. Japanese Society for Cancer of the Colon and Rectum: Multi-institutional registry of large bowel cancer in Japan, Cases treated in 2000鈥?002, vol. 29 (2011), Cases treated in 2003鈥?004, vol. 30 (2012)
  30. Heald, RJ, Husband, EM, Ryall, RD (1982) The mesorectum in rectal cancer surgery鈥攖he clue to pelvic recurrence?. Br J Surg 69: pp. 613-616
  31. MacFarlane, JK, Ryall, RD, Heald, RJ (1993) Mesorectal excision for rectal cancer. Lancet 341: pp. 457-460
  32. Enker, WE, Thaler, HT, Cranor, ML (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181: pp. 335-346
  33. Lowry, AC, Simmang, CL, Boulos, P (2001) Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 44: pp. 915-919
  34. Sugihara, K, Kobayashi, H, Kato, T (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49: pp. 1663-1672
  35. Murata, S, Moriya, Y, Akasu, T (1998) Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83: pp. 1086-1093
  36. Kobayashi, K, Kawamura, M, Ishihara, T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118: pp. 1090-1096
  37. Portier, G, Elias, D, Bouche, O (2006) Multicentric randomized trial of adjuvant fluorouracil and folnic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24: pp. 4976-4982
  38. Mitry, E, Fields, AL, Bleiberg, H (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26: pp. 4906-4911
  39. Robinson, BJ, Rice, TW, Strong, SA (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer?. J Thorac Cardiovasc Surg 117: pp. 66-76
  40. Lambert, LA, Colacchio, TA, Barth, RJ (2000) Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 135: pp. 473-479
  41. Adam, R (2007) Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34: pp. S7-S11
  42. Lam, VW, Spiro, C, Laurence, JM (2012) A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19: pp. 1292-1301
  43. Regnard, JF, Grunenwald, D, Spaggiari, L (1998) Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66: pp. 214-218
  44. Beppu, T, Matsuda, T, Maeda, K (2000) Microwave coagulation therapy for metastatic liver tumor. Surg Therapy 83: pp. 237-242
  45. Shibata, T, Niinobu, T, Ogata, N (2000) Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 89: pp. 276-284
  46. Park, IJ, Kim, HC, Yu, CS (2008) Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 15: pp. 227-232
  47. Wong, SL, Mangu, PB, Choti, MA (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28: pp. 493-508
  48. Tree, AC, Khoo, VS, Eeles, RA (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14: pp. e28-e37
  49. Patchell, RA, Tibbs, PA, Walsh, JW (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: pp. 494-500
  Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: pp. 1444-1450
  50. Benson, AB, Schrag, D, Somerfield, MR (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: pp. 3408
  51. Schmoll, HJ, Cutsem, E, Stein, A (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23: pp. 2479-2516
  52. Haller, DG, Catalano, PJ, Macdonald, JS (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23: pp. 8671-8678
  53. Scheithauer, W, Rosen, H, Kornek, GV (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: pp. 752-755
  54. Simmonds, PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 321: pp. 531-535
  55. Cunningham, D, Pyrhonen, S, James, RD (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: pp. 1413-1418
  56. Gramont, A, Figer, A, Seymour, M (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: pp. 2938-2947
  57. Goldberg, R, Sargent, D, Morton, R (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: pp. 23-30
  58. Saltz, LB, Clarke, S, D铆az-Rubio, E (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26: pp. 2013-2019
  59. Cassidy, J, Clarke, S, D铆az-Rubio, E (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: pp. 2006-2012
  60. Tournigand, C, Andr茅, T, Achille, E (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: pp. 229-237
  61. Douillard, JY, Cunningham, D, Roth, AD (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: pp. 1041-1047
  62. Fuchs, CS, Marshall, J, Mitchell, E (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC鈥揅 Study. J Clin Oncol 25: pp. 4779-4786
  63. Fuchs, CS, Marshall, J, Barrueco, J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC鈥揅 study. J Clin Oncol 26: pp. 689-690
  64. Bokemeyer, C, Bondarenko, I, Makhson, A (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: pp. 663-671
  65. Douillard, JY, Siena, S, Cassidy, J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin(FOLFOX4)versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: pp. 4697-4705
  66. Cutsem, E, K枚hne, CH, Hitre, E (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: pp. 1408-1417
  67. K枚hne, CH, Hofheinz, R, Mineur, L (2012) First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138: pp. 65-72
  68. Falcone, A, Ricci, S, Brunetti, I (2007) Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan(FOLFOXIRI)compared with infusional fluorouracil, leucovorin, and irinotecan(FOLFIRI)as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: pp. 1670-1676
  69. Petrelli, N, Herrera, L, Rustum, Y (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: pp. 1559-1565
  70. Gramont, A, Bosset, JF, Milan, C (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: pp. 808-815
  71. Hurwitz, H, Fehrenbacher, L, Hainsworth, JD (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: pp. 3502-3508
  72. Kabbinavar, F, Hurwitz, HI, Fehrenbacher, L (2003) Phase II, randomized trial comparing Bevacizumab plus fluorouracil(FU)/leucovorin(LV)with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: pp. 60-65
  73. Hoff, PM, Ansari, R, Batist, G (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: pp. 2282-2292
  74. Cutsem, E, Twelves, C, Cassidy, J (2001) Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: pp. 4097-4106
  75. Tebbutt, NC, Wilson, K, Gebski, VJ (2010) Capecitabine, bevacizumab, and mitomycin in first鈥搇ine treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28: pp. 3191-3198
  76. Shirao, K, Hoff, PM, Ohtsu, A (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur(UFT)plus oral leucovorin(LV)regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22: pp. 3466-3474
  77. Douillard, JY, Hoff, PM, Skillings, JR (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: pp. 3605-3616
  78. Carmichael, J, Popiela, T, Radstone, D (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: pp. 3617-3627
  79. Bennouna, J, Sastre, J, Arnold, D (2013) ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol 14: pp. 29-37
  80. Muro, K, Boku, N, Shimada, Y (2010) Irinotecan plus S-1 (IRIS)versus fluorouracil and folinic acid plus irinotecan (FOLFIRI)as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11: pp. 853-860
  81. Sobrero, AF, Maurel, J, Fehrenbacher, L (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: pp. 2311-2319
  82. Peeters M, Price TJ, Hotko YS, et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Patient-reported outcomes (PRO). 2010 ASCO Gastrointestinal Cancers Symposium. (Abstr 282)
  83. Rothenberg, ML, Oza, AM, Bigelow, RH (2003) Superiority of oxaliplatin and fluorouracil鈥搇eucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil鈥搇eucovorin: interim results of a phase III trial. J Clin Oncol 21: pp. 2059-2069
  84. Giantonio, BJ, Catalano, PJ, Meropol, NJ (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: pp. 1539-1544
  85. Rothenberg, ML, Cox, JV, Butts, C (2008) Capecitabine plus oxaliplatin (XELOX)versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4)as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19: pp. 1720-1726
  86. Cunningham, D, Humblet, Y, Siena, S (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: pp. 337-345
  87. Jonker, DJ, O鈥機allaghan, CJ, Karapetis, CS (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: pp. 2040-2048
  88. Karapetis, CS, Khambata-Ford, S, Jonker, DJ (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: pp. 1757-1765
  89. Cutsem, E, Peeters, M, Siena, S (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy鈥搑efractory metastatic colorectal cancer. J Clin Oncol 25: pp. 1658-1664
  90. Amado, RG, Wolf, M, Peeters, M (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: pp. 1626-1634
  91. Grothey, A, Cutsem, E, Sobrero, A (2013) CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: pp. 303-312
  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: pp. 252-258
  92. Skibber, JM, Hoff, PM, Minsky, BD Cancer of the rectum. In: Devita, VT, Hellman, S, Rosenberg, SA eds. (2001) Cancer: principles and practice of oncology. Lippincott, Williams and Wilkins, Philadelphia, pp. 1271-1318
  Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336: pp. 980-987
  93. Camma, C, Giunta, M, Fiorica, F (2000) Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 284: pp. 1008-1015
  Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 358: pp. 1291-1304
  94. Kapiteijn, E, Marijnen, CA, Nagtegaal, ID (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: pp. 638-646
  95. Peeters, KC, Marijnen, CA, Nagtegaal, ID (2007) The TME trial after a median follow-up of 6聽years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246: pp. 693-701
  96. Gijn, W, Marijnen, CA, Nagtegaal, ID (2011) Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12: pp. 575-582
  97. Marijnen, CA, Velde, CJ, Putter, H (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23: pp. 1847-1858
  98. Peeters, KC, Velde, CJ, Leer, JW (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol 23: pp. 6199-6206
  99. Francois, Y, Nemoz, CJ, Baulieux, J (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 17: pp. 2396-2402
  Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355: pp. 1114-1123
  100. Gerard, JP, Conroy, T, Bonnetain, F (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24: pp. 4620-4625
  101. Bujko, K, Nowacki, MP, Nasierowska-Guttmejer, A (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93: pp. 1215-1223
  102. Ngan, SY, Burmeister, B, Fisher, RJ (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30: pp. 3827-3833
  103. Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731鈥?740
  104. Hofheinz, RD, Wenz, F, Post, S (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13: pp. 579-588
  105. Roh, MS, Yothers, GA, O鈥機onnell, MJ (2011) The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R鈥?4. J Clin Oncol (Meeting Abstracts) 29: pp. 3503
  106. Aschele, C, Cionini, L, Lonardi, S (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR鈥?1 randomized phase III trial. J Clin Oncol 29: pp. 2773-2780
  107. G茅rard, JP, Azria, D, Gourgou-Bourgade, S (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405鈥揚rodige 2. J Clin Oncol 28: pp. 1638-1644
  108. G茅rard, JP, Azria, D, Gourgou-Bourgade, S (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30: pp. 4558-4565
  109. R枚del, C, Liersch, T, Becker, H (2012) German Rectal Cancer Study Group: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO鈥?4 randomised phase 3 trial. Lancet Oncol 13: pp. 679-687
  110. Cancer pain relief and palliative care (1990) Report of a WHO expert committee. WHO Technical Report Series 804. WHO, Geneva, 21鈥?2
  111. Renehan, AG, Egger, M, Saunders, MP (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 324: pp. 813-816
  112. Figueredo, A, Rumble, RB, Maroun, J (2003) Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 6: pp. 26
  113. Renehan, AG, Egger, M, Saunders, MP (2005) Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 92: pp. 430-433
  114. Jeffery M, Hickey BE, Hider PN (2007) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 24: CD002200
  115. Tjandra, JJ, Chan, MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50: pp. 1783-1799
  116. Bruinvels, D, Stiggelbout, A, Kievit, J (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219: pp. 174-182
  117. Fleischer, D, Goldberg, S, Browning, T (1989) Detection and surveillance of colorectal cancer. JAMA 261: pp. 580-585
  118. Green, RJ, Metlay, JP, Propert, K (2002) Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Int Med 136: pp. 261-269
  119. Berman, J, Cheung, R, Weiberg, D (2000) Surveillance after colorectal cancer resection. Lancet 355: pp. 395-399
  120. Japanese Society for Cancer of the Colon and Rectum (2012) JSCCR Guidelines 2012 for the Clinical Practice of Hereditary Colorectal Cancer. Kanehara & CO., LTD. Tokyo
  121. Ueno, H, Mochizuki, H, Hashiguchi, Y (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127: pp. 385-394
  122. Kitajima, K, Fujimori, T, Fujii, S (2004) Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 39: pp. 534-543
  123. Tanaka, S, Haruma, K, Oh-e, H (2000) Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 7: pp. 783-788
  124. Japanese Society for Cancer of the Colon and Rectum (1980) General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. The 2nd Edition. Kanehara & CO., LTD. Tokyo
  125. Japanese Society for Cancer of the Colon and Rectum (1994) General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. The 5th Edition. Kanehara & CO., LTD. Tokyo
  126. Japanese Society for Cancer of the Colon and Rectum (2005) JSCCR Guidelines 2005 for the Treatment of Colorectal Cancer. Kanehara & CO., LTD. Tokyo
  127. Oka, S, Tanaka, S, Kanao, H (2011) Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma: summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig Endosc 23: pp. 190-194
  128. Matsuda, T, Fukuzawa, M, Uraoka, T (2011) Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study. Cancer Sci 102: pp. 1693-1697
  129. Ikematsu, H, Yoda, Y, Matsuda, T (2013) Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 144: pp. 551-559
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Surgical Oncology
  Radiotherapy
  Diagnostic Radiology
  Internal Medicine
  Pathology
  
• 出版者：Springer Japan
• ISSN：1437-7772

文摘

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women and the third largest number among men. Many new methods of treatment have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2014 for treatment of colorectal cancer (JSCCR Guidelines 2014) have been prepared as standard treatment strategies for colorectal cancer, to eliminate treatment disparities among institutions, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding among health-care professionals and patients by making these guidelines available to the general public. These guidelines have been prepared as a result of consensuses reached by the JSCCR Guideline Committee on the basis of careful review of evidence retrieved by literature searches and taking into consideration the medical health insurance system and actual clinical practice in Japan. They can, therefore, be used as a guide for treating colorectal cancer in clinical practice. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions of the Guideline Committee, controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories, on the basis of consensus reached by Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2014.